Aleksandra Gentry-Maharaj
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (21)
Figure S3 shows posterior predictive checks for the primary analysis among HGSC cancers across all trial arms, comparing observed data with model predictions for clinical and screen-detected cancers.
Year:
2025
Figure S1 shows predictive model fits from approximate leave-one-out cross-validation for the full dataset and for cancer cases only, highlighting model selection steps and the final chosen model.
Year:
2025
Figure S7 shows posterior predictive checks for an analysis with episode-specific MMS sensitivities, comparing observed data with model predictions for clinical and screen-detected cancers across all trial arms.
Year:
2025
Supplementary Methods describe the model selection process using approximate leave-one-out cross-validation, posterior predictive checks comparing predicted and observed cancer incidence, and the estimation of empirical screening sensitivities from the fitted natural history model.
Year:
2025
Figure S6 shows the sensitivity of parameter estimates to model structure, displaying medians and credible intervals for onset rate, mean preclinical phase, and MMS/USS sensitivities across well-fitting models.
Year:
2025
Background: The UK Collaborative Trial of Ovarian Cancer Screening did not detect a reduction in ovarian cancer mortality with either multimodal screening (MMS) or transvaginal ultrasound screening (USS) compared with no screening. The trial data provide an invaluable resource to quantify the opportunity for interception in ovarian cancer. Methods: We used Bayesian inference to estimate ovarian cancer natural history based on individual screening and cancer diagnosis records from the UK Collaborative Trial of Ovarian Cancer Screening, a randomized controlled ovarian cancer screening trial conducted in England, Wales, and Northern Ireland. The trial included 202,638 women ages 50 to 74 years with no family history of ovarian cancer, randomized in a 1:1:2 ratio to annual MMS (serum CA125 interpreted using the risk of ovarian cancer algorithm), annual USS, or no screening. The current analysis included 199,499 women, with 674,806 screens and 2,025 cancer diagnoses. Results: Among high-grade serous cancers (HGSC), the estimated preclinical detectable phase was 1.7 years (95% credible interval, 1.3–2.2), compared with 7.8 years (95% credible interval, 5.7–10.6) for non-HGSCs. The preclinical detectable phase depended on screening modality: for HGSCs, it was longer in the MMS arm (2.2 years) compared with the USS arm (0.8 years), whereas for non-HGSCs, it was shorter in the MMS arm (2.7 years) compared with the USS arm (8.2 years). Conclusions: The interception opportunity for ovarian cancer strongly depends on histologic subtype and screening modality. Impact: Achieving a clinically significant benefit of ovarian cancer early detection will require prolonging the interception window through judicious combination of first- and second-line tests.
Year:
2025
Background: Ovarian high-grade serous carcinomas (HGSC) comprise four distinct molecular subtypes based on mRNA expression patterns, with differential survival. Understanding risk factor associations is important to elucidate the etiology of HGSC. We investigated associations between different epidemiologic risk factors and HGSC molecular subtypes. Methods: We pooled data from 11 case–control studies with epidemiologic and tumor gene expression data from custom NanoString CodeSets developed through a collaboration within the Ovarian Tumor Tissue Analysis consortium. The PrOTYPE-validated NanoString-based 55-gene classifier was used to assign HGSC gene expression subtypes. We examined associations between epidemiologic factors and HGSC subtypes in 2,070 cases and 16,633 controls using multivariable-adjusted polytomous regression models. Results: Among the 2,070 HGSC cases, 556 (27%) were classified as C1.MES, 340 (16%) as C5.PRO, 538 (26%) as C2.IMM, and 636 (31%) as C4.DIF. The key factors, including oral contraceptive use, parity, breastfeeding, and family history of ovarian cancer, were similarly associated with all subtypes. Heterogeneity was observed for several factors. Former smoking [OR = 1.25; 95% confidence interval (CI) = 1.03, 1.51] and genital powder use (OR = 1.42; 95% CI = 1.08, 1.86) were uniquely associated with C2.IMM. History of endometriosis was associated with C5.PRO (OR = 1.46; 95% CI = 0.98, 2.16) and C4.DIF (OR = 1.27; 95% CI = 0.94, 1.71) only. Family history of breast cancer (OR = 1.44; 95% CI = 1.16, 1.78) and current smoking (OR = 1.40; 95% CI = 1.11, 1.76) were associated with C4.DIF only. Conclusions: This study observed heterogeneous associations of epidemiologic and modifiable factors with HGSC molecular subtypes. Impact: The different patterns of associations may provide key information about the etiology of the four subtypes.
Year:
2025
Black women are twice as likely to die from endometrial cancer (EC) compared with white women. This represents one of the worst racioethnic disparities amongst all cancers globally. Compared with white women, black women are more likely to be diagnosed with advanced EC, have more barriers to accessing care and experience increased delays in obtaining an EC diagnosis and commencing treatment. Histological and molecular differences place black women at higher risk of being diagnosed with more aggressive EC subtypes that carry less favourable outcomes. Furthermore, EC diagnostic pathways are less reliable in black women, and black women are less likely to receive evidence-based treatment for EC. This racioethnic disparity in EC outcomes exists both in the UK and US, despite differences in healthcare systems. This review methodically describes the key factors along the patient journey that contribute to the disparity in black women and proposes multifaceted approaches to lessen these gaps.
Year:
2024
Cervical cancer causes 350,000 deaths annually, with 90% occurring in low and middle-income countries (LMICs), despite being largely preventable through vaccination and screening. This review examines innovative approaches to address screening coverage gaps worldwide, analysing both established programs in high-income countries and implementation strategies for LMICs. Self-sampling technologies demonstrate significant potential to increase screening participation by 1.5 to 2.5 times compared to traditional methods, particularly benefiting underserved populations across all healthcare settings. Vaginal brushes achieve the highest sensitivity (94.6%, 95% CI: 92.4-96.8) for HPV detection, while novel approaches like tampon sampling show promising acceptability and performance metrics. Implementation strategies vary by healthcare context, with high-income countries achieving success through integrated screening programs and digital solutions, while LMICs demonstrate effective adaptation through community-based distribution (20-35% uptake) and innovative delivery methods. In resource-limited settings, self-sampling increases participation through enhanced patient comfort and cultural acceptability, while reducing costs by 32-48%. Progress toward the WHO's cervical cancer elimination goals require careful consideration of local healthcare infrastructure, cultural contexts, and sustainable financing mechanisms. Future research priorities include optimising self-sampling technologies for sustainability and scalability, developing context-specific implementation strategies, and validating artificial intelligence applications to enhance screening efficiency across diverse healthcare settings.
Year:
2024
Characterization of HGSC with co-loss of RB1 and BRCA . A, GSEA indicating up- and downregulated pathways in tumors according to BRCA and RB1 status. RB1 -alt, RB1 altered; RB1 -wt, RB1 wild-type. B, Boxplots comparing GSVA pathway enrichment scores of the cGAS-STING and Toll-like receptor signaling pathways between molecular subgroups; points represent each sample, boxes show the interquartile range (25th–75th percentiles), central lines indicate the median, and whiskers show the smallest/largest values within 1.5 times the interquartile range. Colored boxes with black points indicate the HRD and/or RB1 altered groups, whereas the gray boxes with gray points indicate the HRP and RB1 wild-type group. P values were calculated using a two-sided Mann–Whitney-Wilcoxon test. Benjamini–Hochberg adjusted P values are shown above each pairwise comparison (*, P P P ≥ 0.05). C, Bubble plot summary of HLA gene expression comparisons using DESeq2 between HGSC tumors grouped by HRD and/or RB1 status as shown. The size of the bubbles corresponds to the negative log 10 Benjamini–Hochberg adjusted P value ( P adj ) and only values with P adj ≤ 0.1 are shown. The color and intensity correspond to the log 2 fold change. Genes are grouped by their classes. D, Proportion of TILs in HGSC tumors grouped by RB1 protein expression and BRCA germline status. χ 2 P value is indicated. E, Proportion of tumors classified as each HGSC molecular subtype ( 13 ) grouped by RB1 expression and BRCA germline status. χ 2 P value is indicated. C4.DIF, C4/differentiated subtype; C2.IMM, C2/immunoreactive subtype; C1.MES, C1/mesenchymal subtype; C5.PRO, C5/proliferative subtype.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (44)
Kathryn Terry
Co-Scientific Director
Boston Children's Hospital
Elizabeth Christie
Peter MacCallum Cancer Institute
Timothy Budden
Lecturer
University of Liverpool
Beth Karlan
Vice Chair
University of California, Los Angeles
Anna Jakubowska
Head
Pomeranian Medical University
Lynne Wilkens
Professor
University of Hawaii at Manoa
Anthony Swerdlow
Professor of Epidemiology
Institute of Cancer Research Sutton
Martin Widschwendter
Professor; Director
University of Innsbruck
P. M. Webb
Group Leader
QIMR Berghofer Medical Research Institute
Martin Köbel
Associate Professor
University of Calgary
James D Brenton
University of Cambridge
Cezary Cybulski
Pomeranian Medical University
Lindsay J Collin
Assistant Professor
Emory University
Jason Xu
Duke University
Linda Cook
Professor
University of Colorado Cancer Center
Angela Brooks-Wilson
Simon Fraser University
Tomasz Kluz
Professor
Rzeszów University
Joellen Schilkdraut
Professor
Emory University
Michael Anglesio
Associate Professor
The University of British Columbia
Ramona Erber
W2-Professorin, Oberärztin
University of Regensburg
Usha Menon
Professor of Gynaecological Oncology
University College London
Jane Lange
Staff Scientist
Oregon Health & Science University
Sandra Orsulic
Professor
University of California, Los Angeles
Cheng-Han Lee
Associate Professor
University of Alberta
Ian Campbell
Group Leader
Peter MacCallum Cancer Institute
Stacey J. Winham
Mayo Clinic College of Medicine and Science
Anna H. Wu
Professor
University of Southern California
C Blake Gilks
-
Peter Fasching
-
Francesmary Modugno
University of Pittsburgh
Alexander Hein
-
Dale Garsed
University of Melbourne
Renée Fortner
Head of Division
Deutsches Krebsforschungszentrum
K Sundfeldt
Professor/Consultant
University of Gothenburg, Sahlgrenska Academy
Gregg Nelson
Gynecologic Oncologist
University of Calgary
Jennifer Anne Doherty
Professor
University of Utah
Paul Pharoah
Professor of Cancer Epidemiology
Cedars-Sinai Medical Center
Brenda Y Hernandez
University of Hawaii
Michael Edwin Jones
Senior Staff Scientist
Institute of Cancer Research
Jan Lubiński
Head of Dept
Pomeranian Medical University
Mona El-Bahrawy
Imperial College London
David G. Huntsman
The University of British Columbia
Susan Ramus
Professor of Molecular Oncology
University of New South Wales
Aline Talhouk
Assistant Professor
The University of British Columbia
Make your next move.
Prepare your application
Review drafts before you send them.